Growing Expectations COVID Vaccine Could Be Ready By End Of Year

Nachrichtenquelle: PR Newswire (engl.)
04.08.2020, 14:45  |  300   |   |   

Financialnewsmedia.com News Commentary

PALM BEACH, Florida, Aug. 4, 2020 /PRNewswire/ -- It seems lately, that news on a vaccine (or vaccines) for the global health crisis, project new possibilities moving quickly to the final solution.  The number of vaccines in development seems to be growing daily. Recently, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, testified in Congress, saying that it was a definitely a possibility the United States would have an effective vaccine against COVID-19 by early next year. An article on his testimony from the Center for Infectious Disease Research and Policy added: "His optimism comes on the same day Operation Warp Speed, the US's COVID-19 vaccine program, announced its biggest agreement yet: $2.1 billion to Sanofi Pasteur to supply the US government with 100 million doses of its experimental coronavirus vaccine. Sanofi is working with GlaxoSmithKline on a vaccine clinical trial planned for September."  Active biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO), Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Moderna, Inc. (NASDAQ: MRNA), Gilead Sciences, Inc. (NASDAQ: GILD.

Fauci said he saw promising data on Moderna's vaccine, which began its phase 3 trials on Monday. Moderna's vaccine is also being funded in part by Operation Warp Speed, which has so far spent $8 billion on vaccine development... And in answering questions about China and Russia's progress on a vaccine, Fauci seemed confident the United States would not have to rely on an international vaccine candidate. "I do not believe that there will be vaccines so far ahead of us that we will have to depend on other countries to get us vaccines," he said.  NPR reported additional statements from Fauci: "While it typically takes years to develop vaccines, new technologies, the lack of bureaucratic red tape and the human body's robust immune response to COVID-19 have hastened the process, Dr. Anthony Fauci said.

Nascent Biotech, Inc. (OTCQB: NBIO) BREAKING NEWS: Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19  -  Nascent Biotech (the "Company" or "Nascent"), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled "BCG: a therapeutic modality for COVID-19 and cancers" hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished clinicians and scientists working on the TB / BCG vaccine for COVID-19 and cancer. The event was moderated by Dr Navpaul Singh, Chief Medical Consultant from Nascent Biotech, Inc and live streamed to social media platforms. Live stream recording is available on YouTube: https://www.youtube.com/watch?v=SumCzJOn0nc.

Seite 1 von 5
Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel